Granite Point Capital Management, L.P. Aerie Pharmaceuticals Inc Transaction History

Granite Point Capital Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 10, 2020	SELL	$17.72 - $25.1 $531,600 - $753,000	-30,000 Closed	0 $0
Q3 2019 Oct 30, 2019	SELL	$18.41 - $28.0 $33,138 - $50,400	-1,800 Reduced 5.66%	30,000 $577,000
Q2 2019 Jul 29, 2019	BUY	$28.97 - $48.21 $382,404 - $636,372	13,200 Added 70.97%	31,800 $940,000
Q2 2018 Aug 13, 2018	SELL	$47.85 - $70.45 $306,240 - $450,880	-6,400 Reduced 25.6%	18,600 $1.26 Million
Q1 2018 May 15, 2018	SELL	$51.15 - $61.0 $1.07 Million - $1.28 Million	-21,000 Reduced 45.65%	25,000 $1.36 Million

Q4 2017 Feb 08, 2018	SELL	$50.85 - $65.1 $193,230 - $247,379	-3,800 Reduced 7.63%	46,000 $2.75 Million
Q3 2017 Nov 14, 2017	SELL	$48.6 - $60.1 $590,927 - $730,755	-12,159 Reduced 19.62%	49,800 $2.42 Million
Q2 2017 Aug 10, 2017	BUY	N/A	61,959	61,959 $3.26 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Granite Point Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Granite Point Capital Management, L.P. with notifications on news.